News
News
 |
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 19, 2021NeuroSense filed the F-1 Registration Statement with the SEC on October 18th, 2021.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced...
-
Sep 29, 2021Mr. Leuchtenberger joins the company as a board member and chairperson, effective October 1, 2021.
NeuroSense Therapeutics, a clinical stage biotechnology company in the field of CNS, is pleased to announce the appointment of Mark Leuchtenberger as its new Chairman of the Board of Directors....
-
Mar 2, 2021The study's primary end-point was obtained successfully, and preliminary clinical signals were observed indicating that PrimeC could be an effective therapeutic for patients with ALS.
NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming...
-
Jan 12, 2021NeuroSense, a biotech company developing treatment for ALS, has been granted orphan designation for their first drug, PrimeC, from the European Medicines Agency.
NeuroSense Therapeutics, a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Their treatment...
-
Nov 18, 2020Following 9-months of treatment with PrimeC, NeuroSense's combination drug, positive trends first seen in the 6-month interim analysis persist, indicating therapeutic potential for ALS patients.
NeuroSense Therapeutics, a biotech company developing PrimeC, a combination drug which aims to slow ALS progression, continues to report promising trends in their NST002 Phase IIa study, conducted...
